Clinical Study

S1815- A Phase III Randomized Trial Of Gemcitabine, Cisplatin, And Nab-Paclitaxel Versus Gemcitabine And Cisplatin In Newly Diagnosed, Advanced Biliary Tract Cancers

Posted Date: Oct 1, 2019

  • Investigator: Olugbenga Olowokure
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The purpose of this study is to compare overall survival (OS) in patients with untreated, advanced biliary cancers treated with gemcitabine and cisplatin (GC) versus those treated with gemcitabine, cisplatin, and nab-Paclitaxel (GCN)

Criteria:

To Be Eligible: Must Be Diagnosed With Intra Or Extrahepatic Cholangiocarcinoma Or Gallbladder Cancer, >18 Years Of Age, Nonpregnant/Nonbreastfeeding, No Other Active Infection

Keywords:

Gallbladder Cancer, Oncology, Biliary Cancer

For More Information:

Uc Cancer Center
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.